Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Roivant Sciences Ltd. CEO Matt Cline said the firm’s unit Immunovant Inc. with FcRn blocker batoclimab has established “frankly a new bar” in myasthenia gravis (MG) as the New York-based firm reported ...

The webcast will feature Pete Salzmann, CEO of Immunovant, and Matt Gline, CEO of Roivant. Interested participants ... results from its Phase 3 study of batoclimab in MG and initial results ...